Walgreens Unwraps Holiday Savings for 2025
DEERFIELD, Ill.--(BUSINESS WIRE)--The holidays just got brighter- and more affordable - at Walgreens. From Black Friday through Christmas Day, shoppers can unlock the retailer's most exciting savings ...
Fiscal Year: September - August
Walgreens Boots Alliance, Inc. (WBA), listed on the NASDAQ, has a market capitalization of $. As of Nov 19, 2025, the stock is trading at $11.98 per share, offering investors a clear view of its current market value. Walgreens Boots Alliance, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Walgreens Boots Alliance, Inc. also offers a dividend yield of 7.02%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Walgreens Boots Alliance, Inc. (WBA) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Walgreens Boots Alliance, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Walgreens Boots Alliance, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Walgreens Boots Alliance, Inc. is 0, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Walgreens Boots Alliance, Inc. (WBA) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Walgreens Boots Alliance, Inc. (WBA) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Walgreens Boots Alliance, Inc. (WBA) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Walgreens Boots Alliance, Inc.. To access the full SS Score, consider upgrading your subscription.
Walgreens Boots Alliance, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Walgreens Boots Alliance, Inc. is outperforming or underperforming within its sector.
DEERFIELD, Ill.--(BUSINESS WIRE)--The holidays just got brighter- and more affordable - at Walgreens. From Black Friday through Christmas Day, shoppers can unlock the retailer's most exciting savings ...
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens announced today it is launching the Walgreens Pharmacy Patient Advisory Board to ensure patient voices continue to shape how it delivers pharmacy services, ...
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens has launched the 2025-2026 Respiratory Index, an interactive online tool that tracks flu and COVID-19 activity nationwide using prescription, testing and ov...
DEERFIELD, Ill.--(BUSINESS WIRE)--It's time to party like it's 2025. With celebrating "just because" on the rise1, Walgreens is making it easy and convenient to prepare for any occasion – big or small...
Walgreens on Thursday named retail veteran Mike Motz as its chief executive officer after the U.S. pharmacy chain was taken private by Sycamore Partners, marking a fresh chapter for the company that h...
Sycamore Partners said Thursday (Aug. 28) that it completed its acquisition of Walgreens Boots Alliance and that the businesses that made up WBA are now operating as standalone companies under private...
Walgreens on Thursday named retail veteran Mike Motz as chief executive after the U.S. pharmacy chain was taken private by Sycamore Partners, marking a fresh chapter for the company that has been stru...
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreen Co. (“Walgreens”, or the “Company”), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company ...
NEW YORK--(BUSINESS WIRE)--Sycamore Partners (“Sycamore”) announced today that it has completed its acquisition of Walgreens Boots Alliance, Inc. (the “Company” or “WBA”). Sycamore is acquiring the bu...
The brokerage service is replacing Walgreens Boots Alliance, which is being taken private in a deal with Sycamore Partners that is expected to close soon. Interactive Brokers shares jumped nearly 5% i...
NEW YORK , Aug. 25, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Interactive Brokers Grou...
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Specialty Pharmacy has expanded its limited distribution drug (LDD) network to now include 265 products, placing it among the leading networks in specialty ...
Market volatility from tariffs presents a buying opportunity for quality stocks, especially for long-term investors seeking value in the current dip. Otis Worldwide offers resilience and upside potent...
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is now offering flu shots for anyone three years and older at stores nationwide. Individuals and families can walk into their nearest Walgreens pharmacy or ...
Recent stock price pullbacks in two companies present potential buying opportunities for long-term investors, despite no obvious negative news. I emphasize the importance of distinguishing between tem...
ORLANDO, Fla.--(BUSINESS WIRE)--Premier Medical, a leading primary and multispecialty care provider in Central Florida, today announces a new collaboration with Walgreens to increase access to high-qu...
Walgreens Boots Alliance Inc. has taken a major step forward in its bid to go private after it announced that at the Company's Special Meeting of Shareholders, WBA shareholders had approved the previo...
High-yield S&P 500 stocks can be risky, but 14 "safer" S&P 500 dividend dogs have strong free cash flow to support payouts and are attractive buys. Analyst forecasts suggest top ten S&P 500 dividend d...
Walgreens Boots Alliance shareholders Friday approved private equity firm Sycamore Partners' $10 billion buyout offer for the iconic drugstore chain.
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) (the “Company” or “WBA”) today announced that at the Company's Special Meeting of Shareholders (the “Special Meeting”), W...
Despite new S&P highs, I expect continued market volatility and see a 50/50 chance of recession in the next 6–12 months. The Fed's reluctance to cut rates, ongoing trade tensions, and potential stagfl...
News that Walgreens Boots Alliance quarterly loss was better than expected and pharmacy sales are rising bodes well for a financial turnaround under new private equity ownership.
Walgreens is reportedly seeing an uptick in sales as it prepares to go private. The company released quarterly earnings Thursday (June 26) showing sales of $39 billion, a 7.2% increase from the same q...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.
CNBC's Jim Cramer breaks down why he's keeping an eye on shares of Walgreens.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 256.00M | -170.52% | Est @-170.5% |
| 2026 | 875.00M | 241.80% | Analyst x1 |
| 2027 | 1,498.28M | 71.23% | Est @71.2% |
| 2028 | 2,256.41M | 50.60% | Est @50.6% |
| 2029 | 3,072.33M | 36.16% | Est @36.2% |
| 2030 | 3,822.59M | 24.42% | Est @24.4% |
| 2031 | 4,502.63M | 17.79% | Est @17.8% |
| 2032 | 5,094.61M | 13.15% | Est @13.1% |
| 2033 | 5,598.60M | 9.89% | Est @9.9% |
| 2034 | 5,996.77M | 7.11% | Est @7.1% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 141.00M | 1.00 | 141.00M |
| 2024A | -363.00M | 1.00 | -363.00M |
| 2025E | 256.00M | 1.07 | 239.58M |
| 2026E | 875.00M | 1.14 | 766.36M |
| 2027E | 1.50B | 1.22 | 1.23B |
| 2028E | 2.26B | 1.30 | 1.73B |
| 2029E | 3.07B | 1.39 | 2.21B |
| 2030E | 3.82B | 1.49 | 2.57B |
| 2031E | 4.50B | 1.59 | 2.83B |
| 2032E | 5.09B | 1.70 | 3.00B |
| 2033E | 5.60B | 1.82 | 3.08B |
| 2034E | 6.00B | 1.94 | 3.09B |
| Terminal | 141.20B | 1.94 | 72.77B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.